The Review Of
DIABETIC
STUDIES OPEN ACCESS

Shortening The Path: A Narrative Review Of Multi-Omics Integration In The Diagnostic Medical Laboratory For Rare And Complex Diseases

Almontaserbella Abdulhadi Suror[1], Abdullah Abdulaziz Ibrahim Alghamdi[2], Rami Redha Abdulrasheed Ambon[3], Jaber Mufareh Ali Al Huraysi[4], Dalia Sami Dabash[5], Mohammed Munis R Alhadhrami[6], Mohammed Ali Ahmed Mojammami[7], Ali Hamad Fahad Alsowais[8], Hanan Ali Hassan Shafei[9], Osamah Saleh Mohammed Alateeg[10], Noof Mohammed Almohsen[11], Khalid Mari Abdullah Alsharif[12], Alaa Ahmed Alshuwayshi[13], Maha Mohammed Moteq Almotairi[14]

[1]King Abdullah Medical Complex
[2]King Abdullah Medical Complex
[3]King Abdullah Medical Complex
[4]King Abdullah Medical Complex
[5]King Abdullah Medical Complex
[6]King Abdullah Medical Complex – Jeddah
[7]Abu Arish General Hospital
[8]Wadi Al-Dawasir Hospital, Wadi Al-Dawasir, Ministry of Health
[9]Jazan General Hospital
[10]AlQuwayiyah General Hospital
[11]Laboratory, Imam Abdulrahman Alfaisal Hospital, Riyadh, Ministry of Health
[12]Laboratory, Imam abdulrahman alfaisal hospital, Riyadh, Ministry of Health
[13]Laboratory, Imam abdulrahman alfaisal hospital, Riyadh, Ministry of Health
[14]Laboratory, Imam abdulrahman alfaisal hospital, Riyadh, Ministry of Health

Abstract

Background: The diagnostic odyssey for patients with rare and complex diseases—characterized by protracted, costly, and often inconclusive testing—represents a significant failure of traditional, siloed diagnostic paradigms. The integration of multi-omics data (genomics, transcriptomics, proteomics, metabolomics) within the clinical laboratory promises a paradigm shift from sequential analysis to a holistic, systems biology-based diagnostic model. The successful translation of this approach hinges on its integration across the broader healthcare ecosystem, including radiology, health administration, and nursing.
Aim: This narrative review aims to synthesize current evidence on the convergence of multi-omics platforms within the advanced medical laboratory and to articulate its essential interdependencies with key clinical and operational domains to enable a system-wide transformation in rare disease diagnosis.
Methods: An integrative narrative review methodology was employed. A systematic search of PubMed, Scopus, and Web of Science was conducted for literature published between 2010 and 2024, using terms related to multi-omics, rare diseases, diagnostics, and interdisciplinary care.
Results: Multi-omics integration demonstrably increases diagnostic yield in rare diseases by 10-40% over exome sequencing alone. Its clinical impact is maximized when tightly coupled with quantitative imaging phenotypes from radiology, supported by strategic health administration frameworks for resource allocation and reimbursement, and operationalized by informatics-savvy nursing teams for precision patient management and longitudinal data collection.
Conclusion: Integrated multi-omics represents the vanguard of precision diagnostics, offering a powerful path to end diagnostic uncertainty. Its translation into routine practice necessitates not only new laboratory competencies and bioinformatic standards but also a deliberate, collaborative redesign of workflows with radiology, health administration, and nursing. The future diagnostic paradigm

requires the medical laboratory to evolve from a provider of discrete results into the core of a multidisciplinary, data-integrated care team.

Keywords: Multi-omics; Diagnostic Odyssey; Systems Medicine; Clinical Bioinformatics; Integrated Diagnostics; Rare Diseases.

Introduction

The journey to a definitive diagnosis for individuals with rare or phenotypically complex diseases remains one of the most formidable challenges in modern medicine. This "diagnostic odyssey," often spanning many years and involving numerous specialists, repeated testing, and therapeutic dead-ends, exacts a profound toll on patients, families, and healthcare systems (Sawyer et al., 2016). Historically, the diagnostic approach has been linear and reductionist, guided by the differential diagnosis and sequential testing—first biochemical assays, then targeted gene panels, and increasingly, exome or genome sequencing. While next-generation sequencing (NGS) has revolutionized diagnostic yields, a significant proportion of patients—estimated at 50-60% even after comprehensive genomic testing—remain without a molecular diagnosis (Clark et al., 2018). This diagnostic impasse often stems from the inherent biological complexity of disease, where a single genomic locus provides an incomplete picture of a dynamic, interconnected system.

Concurrently, the landscape of biomedical measurement has been transformed by the advent of high-throughput "omics" technologies (Chen et al., 2023). Genomics maps the static DNA blueprint, transcriptomics captures the dynamic RNA expression, proteomics profiles the functional protein machinery, and metabolomics reflects the ultimate biochemical phenotype. Each layer offers a unique but partial snapshot of the pathophysiological state (Wekesa & Kimwele, 2023). The central thesis of systems medicine is that the integration of these multi-dimensional data layers—multi-omics—can reveal emergent properties and causal networks that are invisible to any single modality. This approach moves beyond the "one gene, one test" model towards a holistic understanding of disease as a perturbed network (Hasin et al., 2017; Ullah et al., 2022).

The medical laboratory, traditionally organized into discrete departments (chemistry, hematology, molecular pathology), now stands at the precipice of a fundamental transformation. It is the logical nexus for this integration, possessing the technical expertise, quality frameworks, and clinical interface necessary. However, evolving into an integrated diagnostics hub requires navigating a confluence of unprecedented challenges: the computational complexity of big data fusion, the interpretative skill to translate multi-omics findings into a coherent clinical narrative, the ethical dilemmas of data-rich testing, and the economic realities of healthcare funding (Mazzarotto et al., 2020).

This narrative review explores the convergence of genomics, transcriptomics, proteomics, and metabolomics within the advanced medical laboratory. It assesses the tangible progress made in using integrated multi-omics to end diagnostic odysseys, guide personalized interventions, and discover novel disease signatures. Furthermore, it provides a critical appraisal of the bioinformatic pipelines, clinical validation hurdles, reporting complexities, and the profound ethical and economic implications of bringing this powerful, systems-level approach into routine diagnostic practice.

The Anatomy of a Diagnostic Odyssey and the Limits of Single-Omics

To appreciate the promise of multi-omics, one must first understand the biological and systemic roots of diagnostic failure (Adachi et al., 2023). A diagnostic odyssey is not merely a delay; it is a systemic cascade of uncertainty. For patients, it translates to anxiety, inappropriate or absent treatment, and financial toxicity. For the healthcare system, it manifests as inefficient resource utilization and mounting costs (Boycott et al., 2017). The biological reasons for these odysseys are manifold. Genetic heterogeneity means hundreds of different genes can cause clinically similar presentations (e.g., intellectual disability, inherited neuropathies). Incomplete penetrance and variable expressivity obscure the genotype-phenotype correlation. The increasing recognition of non-coding pathogenic variants, structural variants, repeat expansions, and complex inheritance patterns (digenic, oligogenic) further complicates the picture (Wright et al., 2018).

First-line genomic tools have intrinsic limitations. Exome sequencing captures only ~2% of the genome, missing deep intronic, regulatory, and structural variants. Genome sequencing, while more comprehensive, generates vast amounts of data of uncertain significance (Peymani et al., 2022).

Critically, a DNA sequence is a static code; it reveals potential but not actual function. It cannot reliably inform on RNA splicing efficiency, protein expression or stability, post-translational modifications, or the downstream metabolic consequences of a variant (Kremer et al., 2017). For example, a variant of uncertain significance (VUS) in a gene may be reclassified as pathogenic if RNA sequencing reveals aberrant splicing or absence of transcript. Similarly, a normal genomic sequence in a patient with a convincing metabolic phenotype may find its explanation in proteomic assays revealing an enzyme deficiency or metabolomic profiling showing a pathognomonic biochemical signature (Muñoz-Pujol et al., 2022). Thus, the diagnostic odyssey often persists because the chosen investigative lens is too narrow. Single-omics approaches, while powerful, provide a two-dimensional sketch of a multi-dimensional problem. The integration of complementary omics layers is required to construct a three-dimensional, mechanistic model of disease, effectively cross-validating findings and illuminating causal pathways from genotype to functional phenotype (Grigalionienė et al., 2023). Figure 1 illustrates the traditional diagnostic odyssey experienced by patients with rare and complex diseases.

Figure 1. The Diagnostic Odyssey in Rare and Complex Diseases

The Multi-Omics Toolkit Technologies and Their Diagnostic Synergies

The practical implementation of multi-omics diagnostics relies on a suite of rapidly maturing technologies, each managed within or in close partnership with the modern medical laboratory (Hong et al., 2022). Genomics, the foundational layer, is dominated by NGS. Whole Genome Sequencing (WGS) is increasingly the genomic tool of choice for rare disease, offering uniform coverage and the ability to detect a broader range of variant types compared to exome sequencing (ES) (Turro et al., 2020). Transcriptomics, typically via RNA sequencing (RNA-seq) from accessible tissues like blood or skin fibroblasts, serves as a powerful functional adjunct. It can validate the pathogenicity of non-coding and splice-region variants by demonstrating allele-specific expression, nonsense-mediated decay, or aberrant splicing (Cummings et al., 2017). In oncology, transcriptomics is pivotal for detecting gene fusions and characterizing expression subtypes (Zhou et al., 2022).

Proteomics has advanced from low-throughput western blotting to mass spectrometry (MS)-based methods. Targeted proteomics can quantify specific proteins, validating the functional impact of a genetic variant at the protein level (e.g., absence of a dystrophin) (Usha Rani et al., 2023). Discovery proteomics can profile thousands of proteins, identifying novel biomarkers or disease subtypes. Metabolomics, the systematic study of small-molecule metabolites, provides the closest readout of cellular phenotype. Using technologies like liquid chromatography-mass spectrometry (LC-MS) or nuclear magnetic resonance (NMR), it can identify inborn errors of metabolism, characterize mitochondrial disorders, and reveal metabolic signatures of dysregulated pathways (Miller et al., 2015).

The diagnostic power lies not in the individual technologies, but in their synergistic integration. The canonical diagnostic cascade begins with an ambiguous WGS finding. RNA-seq can then be deployed

for functional validation. If the RNA is normal but clinical suspicion remains high, targeted proteomics can assess protein quantity and function (Stranneheim et al., 2021). Finally, metabolomics can reveal the downstream biochemical perturbations, confirming the diagnosis and often guiding therapy (e.g., recommending a cofactor or dietary modification). This sequential, hypothesis-driven integration is the most common current model. The frontier, however, involves parallel multi-omics—the simultaneous acquisition and integrated computational analysis of multiple data layers from a single sample, aiming for a unified diagnostic interpretation without pre-defined hypotheses. This approach is computationally intensive but holds the greatest promise for solving the most cryptic cases (Jiang et al., 2023). Figure 2 provides a schematic overview of integrated multi-omics diagnostics within the advanced medical laboratory.

Figure 2. Integrated Multi-Omics Diagnostics in the Medical Laboratory



Bioinformatic Pipelines

The transformation of raw multi-omics data into a clinically actionable result is entirely dependent on robust, reproducible bioinformatics. This represents perhaps the greatest technical challenge for the medical laboratory. The bioinformatic workflow for integrated diagnostics is a multi-stage pipeline far more complex than that for single-modality testing (Table 1).

The process begins with data processing and quality control for each omics layer separately, using tools tailored to the specific technology (GATK for genomics, STAR for transcriptomics, MaxQuant for proteomics) (Pham et al., 2022). The next critical phase is data integration and fusion. This can be achieved through several computational strategies: Vertical integration aligns different data types from the same patient to a common reference (e.g., genomic variant -> transcript -> protein), enabling direct causal inference. Horizontal integration combines data from a cohort of patients to identify shared multi-omics signatures associated with a disease. More advanced methods use network-based approaches, mapping multi-omics data onto biological pathways or protein-protein interaction networks to identify dysregulated modules (Ritchie et al., 2015).

A paramount challenge is interpretation and prioritization. The system must triage millions of data points to highlight the few that are clinically relevant. This requires tiered, knowledge-driven filtering against constantly updated databases of known pathogenic variants, gene-disease associations, and pathway information. Machine learning (ML) and artificial intelligence (AI) are increasingly employed to discover novel patterns, predict variant pathogenicity from multi-omics features, and match patient profiles to known disease signatures (Santiago et al., 2021). However, these "black box" models raise significant challenges for clinical validation and regulatory approval. The final output is not a simple positive/negative result, but an integrated data narrative—a report that synthesizes evidence from

multiple layers into a coherent argument for or against a diagnosis, complete with confidence scores and suggested functional validations. Developing standardized, interoperable, and clinically transparent bioinformatic pipelines is a prerequisite for the scalability and reliability of multi-omics diagnostics.

Table 1: The Multi-Omics Diagnostic Cascade: Technologies, Applications, and Synergies

Omics Layer	Core Technology	Primary Diagnostic Utility	Synergistic Role in Integration	Common Sample Type(s)
Genomics	Next-Generation Sequencing (WGS, WES)	Identifying sequence variants (SNVs, indels), structural variants, mtDNA variants.	Provides the foundational hypothesis. Identifies candidate genes for functional interrogation.	Blood (DNA), Saliva.
Transcriptomics	RNA Sequencing (RNA-seq)	Detecting aberrant splicing, allele-specific expression, gene fusions, expression outliers.	Validates genomic findings. Diagnoses disorders of RNA processing. Can identify pathogenic non-coding variants.	Blood (PAXgene), Skin Fibroblasts, Tissue Biopsy.
Proteomics	Mass Spectrometry (Targeted/Discovery)	Quantifying protein abundance, detecting truncated proteins, identifying post-translational modifications.	Validates functional impact at protein level. Diagnoses disorders of protein stability/trafficking. Biomarker discovery.	Plasma/Serum, CSF, Tissue, Cultured Cells.
Metabolomics	Mass Spectrometry (LC-MS), NMR	Profiling small molecules to identify inborn errors of metabolism, mitochondrial disorders, biochemical signatures.	Reveals functional downstream consequences. Can diagnose disorders with normal genomics. Directly guides dietary/pharmacological therapy.	Plasma, Urine, CSF, Dried Blood Spot.
Integrative Analysis	Bioinformatics Pipelines (Network Analysis, ML)	Fusing multi-omics data to build causal models, identify dysregulated pathways, match to known molecular phenotypes.	Generates a unified diagnostic hypothesis from disparate data. Prioritizes variants of uncertain significance. Discovers novel disease mechanisms.	Multi-omic data matrices from same individual/cohort.

Clinical Impact in Solving Odysseys, Guiding Therapy, and Discovering Biomarkers

The ultimate test of any diagnostic paradigm is its impact on patient care. Emerging evidence robustly demonstrates that multi-omics integration delivers tangible clinical benefits across three key domains: ending diagnostic odysseys, personalizing management, and enabling discovery.

Multiple studies have shown that the sequential addition of RNA-seq to exome or genome sequencing increases diagnostic yield by 10-35% in rare Mendelian diseases, particularly for neurodevelopmental disorders and muscular dystrophies (Frésard et al., 2019; Montgomery et al., 2022). This "seq-ing" combo directly resolves VUS by demonstrating their functional impact. Integrated proteogenomic approaches—combining genomics with mass spectrometry-based proteomics—have successfully diagnosed patients with immune deficiencies and muscular disorders where genomics alone was inconclusive, by revealing absent or abnormal proteins (Smirnov et al., 2023). Metabolomics is routinely diagnostic for many inborn errors of metabolism and is increasingly used to validate and subtype mitochondrial disorders identified by genomics (Jans et al., 2022).

A definitive multi-omics diagnosis often directly informs management. It can identify druggable pathways (e.g., mTOR pathway activation in a rare overgrowth syndrome, suggesting sirolimus), recommend specific supplements or dietary changes (e.g., B-vitamins for certain mitochondrial defects identified by metabolomics), or guide repurposed drug therapy based on the elucidated mechanism. In oncology, integrated genomic and transcriptomic profiling is standard for selecting targeted therapies and immunotherapies. For rare diseases, this shifts care from generic symptom management to mechanism-based intervention.

Multi-omics is a powerful engine for discovering novel, non-invasive biomarkers. By correlating genomic variants with specific proteomic or metabolomic signatures, labs can develop simpler, follow-up biochemical tests for monitoring disease progression or treatment response. Furthermore, integrating omics data from patient cohorts can reveal molecularly distinct subtypes within a clinically homogeneous disease, a critical step towards stratified medicine (Subramanian et al., 2020). These discovered signatures can later be distilled into targeted assays for routine clinical use.

Integration with Radiology, Health Administration, and Nursing

The full potential of multi-omics diagnostics can only be realized through deep, systematic integration with three critical pillars of the healthcare system: radiology, health administration, and nursing (Subramanian et al., 2020).

Correlating Molecular Signatures with Imaging Phenotypes (Radiomics)

The integration of multi-omics with radiology—often termed “radiogenomics” or “radiomics”—creates a powerful diagnostic synergy (Lambin et al., 2017). While omics data reveals the molecular “why,” advanced imaging such as MRI, CT, and PET provides the structural and functional “where” and “how much.” For rare diseases, specific imaging phenotypes can guide targeted omics testing; for example, a distinctive pattern of brain iron accumulation on MRI may directly prompt genetic testing for neurodegeneration with brain iron accumulation disorders (Schneider & Bhatia, 2013). Conversely, an ambiguous multi-omics finding—such as a variant of uncertain significance in a cardiomyopathy gene—can be validated or refuted by precise quantitative imaging metrics of cardiac structure and function (Greene et al., 2023). Quantitative imaging features, or “radiomic signatures,” extracted via artificial intelligence can serve as non-invasive, in vivo biomarkers that correlate with underlying molecular subtypes, enabling disease monitoring without repeated invasive biopsies (Bakas et al., 2018). Realizing this synergy requires establishing shared data platforms and structured reporting protocols where imaging findings and omics data are co-analyzed, moving beyond parallel reporting to truly integrated interpretation (Gillies et al., 2016).

Health Administration in Building the Operational and Economic Framework

Health administrators are the critical enablers for scaling multi-omics from a research endeavor to a routine clinical service (Manolio et al., 2022). Their role encompasses strategic planning and resource allocation, which involves administering the significant capital investment in sequencing and mass spectrometry platforms, high-performance computing infrastructure, and specialized personnel such as clinical bioinformaticians and data scientists (Rehm et al., 2021). A key responsibility is reimbursement and value demonstration, which entails developing innovative payment models to cover the high upfront cost of integrated testing (Payne et al., 2018). This involves conducting rigorous health economic analyses to demonstrate long-term cost savings by ending diagnostic odysseys—thereby preventing unnecessary tests, hospitalizations, and ineffective treatments (Gonzalez et al., 2023). Advocacy for new Current Procedural Terminology codes and value-based bundled payments for diagnostic pathways

is essential (Garrison et al., 2023). Additionally, administrators must lead workflow design and interoperability efforts, redesigning patient pathways to incorporate multi-omics testing at the appropriate juncture and ensuring seamless health information technology interoperability so that omics data can flow into the electronic health record in an actionable format accessible to all relevant specialists (Overby & Tarczy-Hornoch, 2013). Finally, ethical governance and equity require establishing institutional policies for informed consent, data privacy, security, and the reporting of incidental findings, with a core administrative responsibility to develop strategies that promote equitable access and prevent the creation of a two-tier diagnostic system (Bombard et al., 2019).

Nursing as The Bridge to Precision Patient Care

Nursing professionals are the essential human interface that translates complex multi-omics diagnoses into safe, effective, and compassionate patient care (Calzone et al., 2018). Their evolving role begins with pre-test coordination and education, providing clear, compassionate pre-test counseling to explain the scope, potential outcomes, and limitations of multi-omics testing, thereby supporting the informed consent process (Loeb et al., 2022). Precision specimen management is another critical function, ensuring the correct collection, handling, stabilization, and transport of biospecimens critical for different omics assays—such as PAXgene tubes for RNA or rapid processing for metabolomics—which is fundamental for data quality (Ellervik & Vaught, 2015). Following testing, nurses engage in post-test interpretation and care planning, collaborating with genetic counselors and physicians to explain diagnostic results to patients and families and helping them understand the implications for their health and lifestyle (Buaki-Sogo, & Percival, 2020). They are central to implementing precision management plans, such as administering a newly prescribed targeted therapy or educating patients on a specific metabolic diet. Finally, longitudinal monitoring and data collection involve monitoring for treatment response or adverse events linked to a genomically guided therapy, while also facilitating the collection of longitudinal phenotypic data and patient-reported outcomes (Weinshilboum & Wang, 2017). These activities are invaluable for refining genotype-phenotype correlations and assessing the real-world utility of multi-omics testing (Biesecker & Harrison, 2018).

The Evolving Laboratory Report

The complexity of multi-omics data necessitates a complete re-imagination of the laboratory report. The traditional report, presenting a single analyte value or a list of DNA variants with brief interpretations, is insufficient. The integrated multi-omics report is a data-driven narrative that tells the diagnostic story (Chierici et al., 2020). It must synthesize evidence from multiple lines of inquiry, weigh conflicting data, and present a clear, actionable conclusion (Table 2).

Key elements of this next-generation report include: 1) A unified summary statement that provides the integrated diagnosis or conclusion. 2) A results synthesis section that lays out the evidence, layer by layer ("WGS identified a VUS in Gene X. RNA-seq from fibroblasts confirmed aberrant splicing, supporting pathogenicity. Targeted proteomics showed the absence of the protein, confirming the functional impact.") (Nicora et al., 2020). 3) Visual data integration, such as an integrative genomics viewer (IGV) tracks showing genome, transcriptome, and proteomic data aligned, or pathway diagrams highlighting the dysregulated node. 4) Clear clinical correlation and management recommendations directly linked to the findings. 5) An appendix of detailed data for specialists, including access to raw data files in compliance with standards (Ivanisevic & Sewduth, 2023).

This shift turns the laboratory director and clinical bioinformatician into diagnostic synthesists. Their role is to curate and interpret complex data, not merely to validate technical accuracy. It also demands new modes of communication with clinicians, often requiring direct consultation to explain the integrated findings and their implications. The report becomes a living document that may be re-interpreted as knowledge evolves, challenging traditional notions of finality in laboratory medicine (Canzler et al., 2020).

Table 2: Challenges and Proposed Solutions for Implementing Integrated Multi-Omics Diagnostics

Challenge Domain	Specific Barriers	Potential Solutions & Future Directions

Technical & Analytical	• Lack of standardized, validated multi-omics bioinformatic pipelines. • Difficulties in analytical validation of integrated tests. • High computational storage/processing costs. • Sample quality/availability for all omics layers.	• Development of open-source, benchmarked software suites (e.g., GA4GH standards). • Use of reference materials and inter-laboratory comparison programs. • Cloud computing adoption; efficient data compression. • Biobanking protocols optimized for multi-omics.
Interpretive & Clinical	• "Information overload" for clinicians. • Lack of training in integrated data interpretation. • Difficulty establishing clinical utility for regulatory approval. • Managing and reporting secondary/incidental findings across omics layers.	• Investment in decision-support tools and visualization aids. • New curricula for lab professionals and genetic counselors. • Prospective outcome studies measuring impact on diagnosis, management, and cost. • Development of consensus reporting guidelines (e.g., from ACMG, AMP).
Ethical & Legal	• Informed consent for open-ended, data-rich testing. • Data ownership, privacy, and security of highly identifiable multi-omics data. • Potential for discrimination (employment, insurance). • Equity of access due to high cost and complexity.	• Dynamic, tiered consent models allowing patient choice in data use. • Strong encryption, federated learning models to analyze data without centralizing it. • Advocacy for robust legal protections (e.g., GINA expansion). • Development of cost-reduction strategies and advocacy for insurance coverage.
Economic & Operational	• Very high per-test costs with unclear reimbursement. • Need for new laboratory roles (clinical bioinformatician, data scientist). • Long turnaround times for complex analyses. • Intellectual property issues around algorithms and databases.	• Health economic analyses to demonstrate long-term cost savings from ending odysseys. • Development of innovative payment models (e.g., bundled payments for a diagnostic pathway). • Automation of pipeline steps; investment in workforce development. • Promotion of open-science and data-sharing consortia.

Ethical, Legal, and Economic Implications

The implementation of multi-omics diagnostics extends beyond technical hurdles into profound ethical, legal, and economic territory. Ethically, informed consent becomes vastly more complex (Lee & Lee, 2022). How does one adequately consent a patient for a test that may generate millions of data points, with implications across their genome, transcriptome, and metabolome, many of which are not fully understood? Traditional consent is inadequate; there is a shift towards dynamic or tiered consent models that enable patients to have ongoing choice about how their data is used, stored, and re-analyzed (Kaye et al., 2015). The management of incidental findings is magnified; a metabolomic screen for a metabolic disorder might reveal evidence of an unrelated cancer, while proteomics could suggest a previously unknown immune condition. Clear, pre-test protocols outlining the findings that will be reported are essential (Zenker et al., 2022).

Legally, issues of data ownership, privacy, and security are paramount. Multi-omics data is the ultimate personally identifiable information. Robust cybersecurity and clear policies on data sharing for research

are non-negotiable. There is also a significant risk of exacerbating health inequities. These advanced tests are expensive and require sophisticated infrastructure, potentially creating a two-tier system where only the wealthy or well-insured can access them, widening existing diagnostic disparities (Manolio et al., 2022).

Economically, the model is challenging. The upfront costs of equipment, bioinformatics infrastructure, and specialized personnel are enormous (Bouttell et al., 2022). Current reimbursement structures, designed for single-analyte tests, are ill-suited to value-based payment for a comprehensive diagnostic evaluation. Demonstrating cost-effectiveness is crucial. While the per-test cost is high, a successful multi-omics test that ends a years-long odyssey may prevent countless unnecessary consultations, imaging studies, and ineffective treatments, yielding substantial long-term savings for the healthcare system (Gonzalez et al., 2023). New economic models, such as bundled payments for a diagnostic pathway or value-based contracts, must be developed to support sustainable implementation (Payne et al., 2018).

Conclusion and Future Directions

The integration of multi-omics data within the medical laboratory represents a paradigm shift from reactive, siloed testing to proactive, systems-based diagnosis. This approach offers a powerful and ethical shortcut out of the diagnostic odyssey for countless patients with rare and complex diseases, providing not just a diagnostic label but a mechanistic understanding capable of guiding targeted therapy. While the evidence for its diagnostic utility is compelling and continues to grow, the path to routine clinical implementation is strewn with interdependent challenges that extend far beyond the laboratory walls. Success is contingent upon parallel advancements and deep collaboration across the entire healthcare ecosystem. Consequently, the medical laboratory must evolve from a mere producer of data into the integrative hub of a new diagnostic paradigm.

This transformation necessitates: (1) Technical Synthesis, through the development of standardized, clinically validated, and reproducible bioinformatic pipelines; (2) Clinical-Radiological Correlation, by forging formalized pathways for the integrated interpretation of omics data with quantitative imaging phenotypes to create a more complete picture of disease; (3) Administrative Enablement, which involves partnering with health administrators to build sustainable economic models, efficient workflows, and governance structures that recognize the long-term value of precise, timely diagnosis and ensure equitable access; and (4) Nursing Integration, by empowering nursing professionals with the knowledge and tools to serve as the critical bridge, translating complex molecular findings into precision care plans, patient education, and longitudinal monitoring.

The future medical laboratory will therefore function as the core of a multidisciplinary Integrated Diagnostic Unit (IDU), where data from the genome to the metabolome are fused with imaging and clinical data to generate actionable health intelligence. Achieving this vision will require breaking down traditional departmental silos, forging deeper collaborations with radiology, administration, and nursing, and embracing a culture of continuous learning and adaptation. By leading this collaborative transformation, the laboratory can fulfill its highest potential: to illuminate the darkest corners of human disease and translate that light into personalized, effective, and compassionate pathways of care, finally bringing the diagnostic odyssey to an end.

References

1. Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., ... & Wattanasirichaigoon, D. (2023). Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. International journal of environmental research and public health, 20(6), 4732. https://doi.org/10.3390/ijerph20064732
2. Bakas, S., Akbari, H., Sotiras, A., Bilello, M., Rozycki, M., Kirby, J. S., ... & Davatzikos, C. (2017). Advancing the cancer genome atlas glioma MRI collections with expert segmentation labels and radiomic features. Scientific data, 4(1), 1-13. https://doi.org/10.1038/sdata.2017.117
3. Biesecker, L. G., & Harrison, S. M. (2018). The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genetics in Medicine, 20(12), 1687-1688. https://doi.org/10.1038/gim.2018.42
4. Bombard, Y., Brothers, K. B., Fitzgerald-Butt, S., Garrison, N. A., Jamal, L., James, C. A., ... & Levy, H. P. (2019). The responsibility to recontact research participants after reinterpretation of

genetic and genomic research results. The American Journal of Human Genetics, 104(4), 578-595. https://doi.org/10.1016/j.ajhg.2019.02.025
5. Bouttell, J., Heggie, R., Oien, K., Romaniuk, A., VanSteenhouse, H., von Delft, S., & Hawkins, N. (2022). Economic evaluation of genomic/genetic tests: a review and future directions. International journal of technology assessment in health care, 38(1), e67.
6. Boycott, K. M., Rath, A., Chong, J. X., Hartley, T., Alkuraya, F. S., Baynam, G., ... & Lochmüller, H. (2017). International cooperation to enable the diagnosis of all rare genetic diseases. The American Journal of Human Genetics, 100(5), 695-705. https://doi.org/10.1016/j.ajhg.2017.04.003
7. Buaki-Sogo, M., & Percival, N. (2020). Genomic medicine: The role of the nursing workforce. Nurs. Times, 118, 1-3.
8. Calzone, K. A., Kirk, M., Tonkin, E., Badzek, L., Benjamin, C., & Middleton, A. (2018). The global landscape of nursing and genomics. Journal of nursing scholarship, 50(3), 249-256. https://doi.org/10.1111/jnu.12380
9. Canzler, S., Schor, J., Busch, W., Schubert, K., Rolle-Kampczyk, U. E., Seitz, H., ... & Hackermüller, J. (2020). Prospects and challenges of multi-omics data integration in toxicology. Archives of Toxicology, 94(2), 371-388. https://doi.org/10.1007/s00204-020-02656-y
10. Chen, C., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., ... & Liu, G. P. (2023). Applications of multi-omics analysis in human diseases. MedComm, 4(4), e315. https://doi.org/10.1002/mco2.315
11. Chierici, M., Bussola, N., Marcolini, A., Francescatto, M., Zandonà, A., Trastulla, L., ... & Furlanello, C. (2020). Integrative network fusion: a multi-omics approach in molecular profiling. Frontiers in oncology, 10, 1065. https://doi.org/10.3389/fonc.2020.01065
12. Clark, M. M., Stark, Z., Farnaes, L., Tan, T. Y., White, S. M., Dimmock, D., & Kingsmore, S. F. (2018). Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ genomic medicine, 3(1), 16. https://doi.org/10.1038/s41525-018-0053-8
13. Cummings, B. B., Marshall, J. L., Tukiainen, T., Lek, M., Donkervoort, S., Foley, A. R., ... & MacArthur, D. G. (2017). Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Science translational medicine, 9(386), eaal5209. https://doi.org/10.1126/scitranslmed.aal5209
14. Ellervik, C., & Vaught, J. (2015). Preanalytical variables affecting the integrity of human biospecimens in biobanking. Clinical chemistry, 61(7), 914-934. https://doi.org/10.1373/clinchem.2014.228783
15. Frésard, L., Smail, C., Ferraro, N. M., Teran, N. A., Li, X., Smith, K. S., ... & Montgomery, S. B. (2019). Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nature medicine, 25(6), 911-919. https://doi.org/10.1038/s41591-019-0457-8
16. Garrison Jr, L. P., Lo, A. W., Finkel, R. S., & Deverka, P. A. (2023, March). A review of economic issues for gene-targeted therapies: Value, affordability, and access. In American Journal of Medical Genetics Part C: Seminars in Medical Genetics (Vol. 193, No. 1, pp. 64-76). Hoboken, USA: John Wiley & Sons, Inc.. https://doi.org/10.1002/ajmg.c.32037
17. Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016). Radiomics: images are more than pictures, they are data. Radiology, 278(2), 563-577. https://doi.org/10.1148/radiol.2015151169
18. Gonzalez, F. S., Mordaunt, D., Stark, Z., Dalziel, K., Christodoulou, J., & Goranitis, I. (2023). Microcosting diagnostic genomic sequencing: a systematic review. Genetics in Medicine, 25(6), 100829. https://doi.org/10.1016/j.gim.2023.100829
19. Greene, D., Genomics England Research Consortium, Pirri, D., Frudd, K., Sackey, E., Al-Owain, M., ... & Turro, E. (2023). Genetic association analysis of 77,539 genomes reveals rare disease etiologies. Nature Medicine, 29(3), 679-688. https://doi.org/10.1038/s41591-023-02211-z
20. Grigalionienė, K., Burnytė, B., Ambrozaitytė, L., & Utkus, A. (2023). Wide diagnostic and genotypic spectrum in patients with suspected mitochondrial disease. Orphanet Journal of Rare Diseases, 18(1), 307. https://doi.org/10.1186/s13023-023-02921-0
21. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome biology, 18(1), 83. https://doi.org/10.1186/s13059-017-1215-1

22. Hong, S. E., Kneissl, J., Cho, A., Kim, M. J., Park, S., Lee, J., ... & Choi, M. (2022). Transcriptome-based variant calling and aberrant mRNA discovery enhance diagnostic efficiency for neuromuscular diseases. Journal of Medical Genetics, 59(11), 1075-1081. https://doi.org/10.1136/jmedgenet-2021-108307
23. Ivanisevic, T., & Sewduth, R. N. (2023). Multi-omics integration for the design of novel therapies and the identification of novel biomarkers. Proteomes, 11(4), 34. https://doi.org/10.3390/proteomes11040034
24. Jans, J. J., Broeks, M. H., & Verhoeven-Duif, N. M. (2022). Metabolomics in diagnostics of inborn metabolic disorders. Current Opinion in Systems Biology, 29, 100409. https://doi.org/10.1016/j.coisb.2021.100409
25. Jiang, S., Wang, H., & Gu, Y. (2023). Genome sequencing for newborn screening—an effective approach for tackling rare diseases. JAMA network open, 6(9), e2331141-e2331141. doi:10.1001/jamanetworkopen.2023.31141
26. Kaye, J., Whitley, E. A., Lund, D., Morrison, M., Teare, H., & Melham, K. (2015). Dynamic consent: a patient interface for twenty-first century research networks. European journal of human genetics, 23(2), 141-146. https://doi.org/10.1038/ejhg.2014.71
27. Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., ... & Prokisch, H. (2017). Genetic diagnosis of Mendelian disorders via RNA sequencing. Nature communications, 8(1), 15824. https://doi.org/10.1038/ncomms15824
28. Lambin, P., Leijenaar, R. T., Deist, T. M., Peerlings, J., De Jong, E. E., Van Timmeren, J., ... & Walsh, S. (2017). Radiomics: the bridge between medical imaging and personalized medicine. Nature reviews Clinical oncology, 14(12), 749-762. https://doi.org/10.1038/nrclinonc.2017.141
29. Lee, H., & Lee, U. (2022). Toward dynamic consent for privacy-aware pervasive health and well-being: A scoping review and research directions. IEEE Pervasive Computing, 21(4), 25-32. https://doi.org/10.1109/MPRV.2022.3210747
30. Loeb, S., Cheng, H. H., Leader, A., Gross, L., Nolasco, T. S., Byrne, N., ... & Giri, V. N. (2022). Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials, 119, 106821. https://doi.org/10.1016/j.cct.2022.106821
31. Manolio, T. A., Rowley, R., Williams, M. S., Roden, D., Ginsburg, G. S., Bult, C., ... & Green, E. D. (2019). Opportunities, resources, and techniques for implementing genomics in clinical care. The Lancet, 394(10197), 511-520. https://doi.org/10.1016/S0140-6736(19)31140-7
32. Mazzarotto, F., Tayal, U., Buchan, R. J., Midwinter, W., Wilk, A., Whiffin, N., ... & Walsh, R. (2020). Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation, 141(5), 387-398. https://doi.org/10.1161/CIRCULATIONAHA.119.037661
33. Miller, M. J., Kennedy, A. D., Eckhart, A. D., Burrage, L. C., Wulff, J. E., Miller, L. A., ... & Elsea, S. H. (2015). Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism. Journal of inherited metabolic disease, 38(6), 1029-1039. https://doi.org/10.1007/s10545-015-9843-7
34. Montgomery, S. B., Bernstein, J. A., & Wheeler, M. T. (2022). Toward transcriptomics as a primary tool for rare disease investigation. Molecular Case Studies, 8(2), a006198. doi:10.1101/mcs.a006198
35. Muñoz-Pujol, G., Alforja-Castiella, S., Casaroli-Marano, R., Morales-Romero, B., García-Villoria, J., Yépez, V. A., ... & Ribes, A. (2022). Diagnostic odyssey in an adult patient with ophthalmologic abnormalities and hearing loss: contribution of RNA-Seq to the diagnosis of a PEX1 deficiency. International Journal of Molecular Sciences, 23(20), 12367. https://doi.org/10.3390/ijms232012367
36. Nicora, G., Vitali, F., Dagliati, A., Geifman, N., & Bellazzi, R. (2020). Integrated multi-omics analyses in oncology: a review of machine learning methods and tools. Frontiers in oncology, 10, 1030. https://doi.org/10.3389/fonc.2020.01030

37. Overby, C. L., & Tarczy-Hornoch, P. (2013). Personalized medicine: challenges and opportunities for translational bioinformatics. Personalized medicine, 10(5), 453-462. https://doi.org/10.2217/pme.13.30
38. Payne, K., Gavan, S. P., Wright, S. J., & Thompson, A. J. (2018). Cost-effectiveness analyses of genetic and genomic diagnostic tests. Nature Reviews Genetics, 19(4), 235-246. https://doi.org/10.1038/nrg.2017.108
39. Peymani, F., Farzeen, A., & Prokisch, H. (2022). RNA sequencing role and application in clinical diagnostic. Pediatric Investigation, 6(01), 29-35. DOI: 10.1002/ped4.12314
40. Pham, H., Reisner, J., Swift, A., Olafsson, S., & Vardeman, S. (2022). Crop phenotype prediction using biclustering to explain genotype-by-environment interactions. Frontiers in Plant Science, 13, 975976. https://doi.org/10.3389/fpls.2022.975976
41. Rehm, H. L., Page, A. J., Smith, L., Adams, J. B., Alterovitz, G., Babb, L. J., ... & Rodarmer, K. W. (2021). GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell genomics, 1(2). https://doi.org/10.1016/j.xgen.2021.100029
42. Ritchie, M. D., Holzinger, E. R., Li, R., Pendergrass, S. A., & Kim, D. (2015). Methods of integrating data to uncover genotype–phenotype interactions. Nature Reviews Genetics, 16(2), 85-97. https://doi.org/10.1038/nrg3868
43. Schneider, S. A., & Bhatia, K. P. (2013). Excess iron harms the brain: the syndromes of neurodegeneration with brain iron accumulation (NBIA). Journal of neural transmission, 120(4), 695-703. https://doi.org/10.1007/s00702-012-0922-8
44. Smirnov, D., Konstantinovskiy, N., & Prokisch, H. (2023). Integrative omics approaches to advance rare disease diagnostics. Journal of Inherited Metabolic Disease, 46(5), 824-838. https://doi.org/10.1002/jimd.12663
45. Stranneheim, H., Lagerstedt-Robinson, K., Magnusson, M., Kvarnung, M., Nilsson, D., Lesko, N., ... & Wedell, A. (2021). Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Medicine, 13(1), 40. https://doi.org/10.1186/s13073-021-00855-5
46. Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020). Multi-omics data integration, interpretation, and its application. Bioinformatics and biology insights, 14, 1177932219899051. https://doi.org/10.1177/1177932219899051
47. Turro, E., Astle, W. J., Megy, K., Gräf, S., Greene, D., Shamardina, O., ... & Ouwehand, W. H. (2020). Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 583(7814), 96-102. https://doi.org/10.1038/s41586-020-2434-2
48. Ullah, I., Yang, L., Yin, F. T., Sun, Y., Li, X. H., Li, J., & Wang, X. J. (2022). Multi-omics approaches in colorectal cancer screening and diagnosis, recent updates and future perspectives. Cancers, 14(22), 5545. https://doi.org/10.3390/cancers14225545
49. Usha Rani, G., Kadali, S., Kurma Reddy, B., Shaheena, D., & Naushad, S. M. (2023). Application of machine learning tools and integrated OMICS for screening and diagnosis of inborn errors of metabolism. Metabolomics, 19(5), 49. https://doi.org/10.1007/s11306-023-02013-x
50. Weinshilboum, R. M., & Wang, L. (2017, November). Pharmacogenomics: precision medicine and drug response. In Mayo Clinic Proceedings (Vol. 92, No. 11, pp. 1711-1722). Elsevier. https://doi.org/10.1016/j.mayocp.2017.09.001
51. Wekesa, J. S., & Kimwele, M. (2023). A review of multi-omics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. Frontiers in Genetics, 14, 1199087. https://doi.org/10.3389/fgene.2023.1199087
52. Zenker, S., Strech, D., Ihrig, K., Jahns, R., Müller, G., Schickhardt, C., ... & Drepper, J. (2022). Data protection-compliant broad consent for secondary use of health care data and human biosamples for (bio) medical research: Towards a new German national standard. Journal of Biomedical Informatics, 131, 104096. https://doi.org/10.1016/j.jbi.2022.104096
53. Zhou, Z., Sang, Q., & Wang, L. (2022). Improving genetic diagnosis of Mendelian disease with RNA sequencing: a narrative review. Journal of Bio-X Research, 5(01), 1-6. https://doi.org/10.1097/JBR.0000000000000100

تقصير المسار: مراجعة سردية لتكامل المتعدد الأوميكس في المختبر الطبي التشخيصي للأمراض النادرة والمعقدة
الملخص

الخلفية :يُعد مسار التشخيص الطويل للمرضى الذين يعانون من أمراض نادرة ومعقدة — والذي يتميز بالاختبارات المطولة والمكلفة وغالباً غير الحاسمة — فشلاً كبيراً في الأساليب التشخيصية التقليدية المعزولة. يعد تكامل بيانات المتعدد الأوميكس داخل المختبر السريري وعدًا بتحول نمطي من التحليل الجيني التسلسلي جينًا بجين إلى نموذج تشخيصي شامل قائم على علم الأحياء النظمي.
الهدف :تهدف هذه المراجعة السردية إلى تلخيص الأدلة الحالية حول التقارب وتكامل منصات المتعدد الأوميكس داخل المختبر الطبي المتقدم.
الطرق :تم استخدام منهجية مراجعة سردية تكاملية. أُجري بحث منهجي في قواعد البياناتPubMed ، Scopus، و Web of Scienceللأدبيات المنشورة بين عامي 2010 و2024.
النتائج :يُظهر تكامل المتعدد الأوميكس زيادة ملحوظة في العائد التشخيصي للأمراض النادرة بنسبة 10-40% مقارنة بتسلسل الإكسوم وحده، خاصة في الاضطرابات التي تشمل المتغيرات غير المشفرة، وعيوب الربط، وخلل التنظيم الوراثي فوق الجيني. ومع ذلك، تظل هناك عوائق رئيسية: غياب إطارات تحليلية موحدة، وتعقيد التفسير، وارتفاع التكاليف، والتحديات الأخلاقية الكبيرة المتعلقة بملكية البيانات، والنتائج العرضية، والتفاوتات الصحية.
الخاتمة :يمثل تكامل المتعدد الأوميكس طليعة التشخيص الدقيق، مقدمًا اختصارًا قويًا لإنهاء عدم اليقين التشخيصي. يتطلب نقل هذا النهج إلى الممارسة الروتينية تطوير كفاءات مخبرية جديدة، ومعايير بيوإنفورماتيكية مصدقة، ونماذج تعويض مبتكرة، وإطارات أخلاقية تعطي الأولوية لاستقلالية المريض. يجب أن يتطور المختبر الطبي من مزود لنتائج منفصلة إلى أمين لروايات بيولوجية معقدة.
الكلمات المفتاحية :متعدد الأوميكس؛ مسار التشخيص الطويل؛ طب النظم؛ بيوإنفورماتيكس سريرية؛ تشخيص متكامل؛ أمراض نادرة.